Prevalence of Rifampicin resistance tuberculosis among presumptive tuberculosis patients in Egypt-2021: a national health facility-based survey
Authors:
Open Access
- 15 February 2024
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-9
Abstract
Background: The magnitude of MDR-TB cases was noticeable in Egypt. However, the last national survey was 11-years ago. The current survey was conducted to determine the prevalence of rifampicin resistance among sputum smear-positive pulmonary tuberculosis patients in Egypt. Methods: A national health facility-based cross-sectional study was conducted in 14 randomly selected governorates in Egypt between August 2020 and September 2021. All presumptive TB cases, either new or previously treated according to WHO definitions, with no gender, age, or nationality limitations, and provided informed consent were included in the study. Each patient completed a case report form (CRF). The CRF included socio-demographic and clinical data. Sputum samples were collected according to standard techniques and cultured on Lowenstein-Jensen (L-J) medium. Gene X-pert test was carried out first on the samples for simultaneous identification of MTB and rifampicin resistance. The prevalence of RR was calculated using crude, cluster, and weighted methods. Factors associated with RR were analyzed by bivariate and multivariate techniques. Results: Among the total 849 presumptive TB patients enrolled in the study, 710 (83.6%) patients were subjected to Gene X-pert testing (MTB/RIF). The crude prevalence of RR was 3.32% (95% CI: 1.89–4.76%) among the new cases and 9.46% (95% CI: 2.63–16.29%) among the retreated cases with an overall estimate of 3.99%; (95% CI: 2.51–5.47%). By cluster analysis the overall prevalence of RR was 5.01% (95% CI: 2.90–7.13). Factors associated with the prevalence of RR were co-morbidity with bronchial asthma, drug abuse and history of contact with a family member with TB. Conclusion: The prevalence of RR among either new or retreated cases TB patients was lower than the previous Egyptian rates in 2010–2012. The strongest predictor associated with RR was comorbidity with bronchial asthma.Keywords
All Related Versions
Funding Information
- Ain Shams University
This publication has 27 references indexed in Scilit:
- Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional surveyThe Lancet Infectious Diseases, 2018
- Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, EthiopiaBMC Public Health, 2018
- Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, PeruPLOS ONE, 2016
- Pattern of Drug Resistance and Risk Factors Associated with Development of Drug Resistant Mycobacterium tuberculosis in PakistanPLOS ONE, 2016
- Multidrug-Resistant Tuberculosis in Patients with Chronic Obstructive Pulmonary Disease in ChinaPLOS ONE, 2015
- Primary drug resistance among pulmonary treatment-naïve tuberculosis patients in Amazonas State, BrazilThe International Journal of Tuberculosis and Lung Disease, 2014
- Involving community partners in the management of tuberculosis among drug usersPublic Health, 2011
- Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?Archives of Medical Science, 2010
- Tuberculosis and Illicit Drug Use: Review and UpdateClinical Infectious Diseases, 2009
- High prevalence of multidrug-resistant tuberculosis in GeorgiaInternational Journal of Infectious Diseases, 2008